What does this research mean for the field?

While most patients show symptomatic improvement three months post-COVID-19 recovery, a significant subset continues to exhibit persistent respiratory dysfunction and structural lung alterations, including fibrotic-like changes. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to investigate chronic pulmonary and systemic abnormalities in patients recovering from COVID-19 three months post-infection.

June 6, 20260 citationsOpen Access

Pulmonary Complications and Systemic Abnormalities in Post-COVID-19 Patients: A 3-Month

FAFarzaneh Akbari ZAZahra Javid Arabshahi SHSepideh Hejazi

Key Points

This research aims to investigate chronic pulmonary and systemic abnormalities in patients recovering from COVID-19 three months post-infection.
Cohort study analyzing 100 patients three months after COVID-19 recovery
Evaluations included spirometry, high-resolution computed tomography, arterial blood gas analysis, and laboratory tests
Excluded patients with preexisting lung diseases or inability to perform spirometry
Persistent cough and dyspnea were reported in a notable proportion of patients despite symptomatic improvement
Spirometry showed ongoing pulmonary dysfunction, with significantly reduced FEV₁ and FVC metrics
CT scans indicated resolution of ground-glass opacities but persistence of fibrotic-like changes in some patients

Abstract

Introduction: The coronavirus disease 2019(COVID-19) pandemic has had significant acute and long-term health impacts. Persistent pulmonary and systemic complications after recovery remain inadequately studied. This cohort study aimed to assess chronic respiratory and systemic abnormalities in patients three months post-COVID-19 recovery.Methods: We evaluated 100 patients more than three months after recovery. Assessments included spirometry, high-resolution computed tomography (HRCT), arterial blood gas (ABG) analysis, and laboratory tests of inflammatory and hematologic parameters. Patients with preexisting lung disease or those to perform spirometry were excluded. Data were analyzed using SPSS version 27.Results: The cohort consisted of 100 patients (mean age 49.8 ± 15.1 years; 50 males, 50 females). While clinical symptoms significantly decreased after three months, cough and dyspnea persisted in a notable proportion. Of the patients, 59.8% were managed as outpatients, 18.5% were hospitalized in general wards, and 21.7% required intensive care unit (ICU) admission. Spirometry revealed ongoing pulmonary dysfunction across obstructive, restrictive, and mixed patterns, with significantly reduced predicted forced expiratory volume in 1 second (FEV₁) and Forced Vital Capacity (FVC). The FEV₁/FVC ratio was notably decreased in obstructive and mixed groups, indicating persistent airflow limitation. Lung Computed Tomography (CT) scan showed significant resolution of ground-glass opacities (80.9% to 18.8%) and consolidation (19.1% to 3.5%). However, fibrotic-like changes, including septal thickening, persisted or slightly increased (21.3% to 32.9%). Other structural abnormalities were uncommon and largely unchanged.Conclusion: Most patients showed symptomatic improvement by three months, but a significant subset continued to exhibit respiratory dysfunction and structural lung alterations. These findings highlight the importance of long-term clinical and radiological monitoring of post-COVID-19 patients and suggest broader implications for managing post-viral respiratory sequelae.

AI से पूछें

Bookmark

View Full Paper